Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Teva Continues To Position Itself For Overseas Opportunities

Executive Summary

The world economic crisis favors generics, as it puts additional pressure on governments already struggling to contain health care spending and reduce other costs, Teva Pharmaceutical CEO Shlomo Yanai told investors on an earnings call Feb. 17

You may also be interested in...

Teva Saw Record Growth In 2008 Across Key Businesses

In contrast to Big Pharma’s doldrums, generics manufacturer Teva had a banner year in 2008 – and expects a strong follow up in 2009.

Side Effects Dampen Neurologists’ Enthusiasm For Novel MS Drugs

With nearly a dozen new multiple sclerosis drugs in some phase of mid- to late-stage development - from the first oral options to infrequently administered biologics - the treatment paradigm for the debilitating disease appears on the cusp of significant change

Teva And Kowa Partner For 50-50 Stake In Japanese Generic Firm

TOKYO - Japanese drug maker Kowa said Sept. 24 that it had signed a definitive agreement with Israel generic manufacturer Teva Pharmaceutical to share a 50-50 stake in a generic manufacturer in Japan to take advantage of a growing Japanese generics market





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts